LIDOCAINE IN VENTRICULAR TACHYCARDIA WITH HEMODYNAMICALLY UNSTABLE WHO REFUSE CARDIOVERSION, IS IT THE FIRST CHOICE OR NOT?
DOI:
https://doi.org/10.29103/averrous.v8i1.7092Keywords:
amiodarone, cardioversion, lidocaine, ventricular tachycardiaAbstract
Sudden cardiac death (SCD) is a vital public health issue, accountable for almost 50% of all cardiovascular deaths. In the last three decades, SCD was the leading cause for almost 230000 to 350000 deaths per annum in the United States. Ventricular arrhythmias account for 25% to 36% of witnessed sudden cardiac arrests (SCA) at home and 38% to 79% of witnessed SCA in public. The goals of ventricular arrhythmia management include symptom relief, improving quality of life, reducing implantable cardioverter defibrillator shocks, preventing deterioration of left ventricular function, reducing risk of arrhythmic death, and potentially improving overall survival. Based on the ACLS guideline, each tachyarrythmia with a pulse should be given synchronized cardioversion, however, when such action could not be performed for various reasons, and showed wide QRS 0,12, intravenous or antiarrthytmia might serve as a possible treatment. If intravena antiarrhytmics are given, amiodarone may be considered. Amiodarone is also effective in preventing recurrence of monomorphic VT. Lidocaine is less effective in terminating VT than procainamide, sotalol and amiodarone. Lidocaine may be considered second-line antiarrthythmic therapy for monomorphic VT.
References
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ PR. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Gui. Circulation. 2018;138(13):210-71.
Spartalis M, Spartalis E, Tzatzaki E, Tsilimigras DI, Moris D, Kontogiannis C, et al. Novel approaches for the treatment of ventricular tachycardia. World J Cardiol. 2017;10(7):52-9.
Yamin M, Harun S. Buku Ajar Ilmu Penyakit Dalam: Aritmia Ventrikel. VI. Interna Publishing; 2015. 1387 p.
Yamin M. Penyakit Kardiovaskular (PKV): Takikardia Ventrikular Apa yang Harus Diwaspadai? IV. Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2016. 411 p.
Foth C, Gangwani MK AH. Ventricular Tachycardia. Treasure Island (FL): StatPearls Publishing; 2021. 2-4 p.
Gopinathannair R, Batul SA, Olshansky B, Fisher JD. Recent advances in the management of ventricular tachyarrhythmias. F1000Research. 2017;6(0).
Garner JB, Miller JM. Clinical Arrhythmias Wide Complex Tachycardia - Ventricular Tachycardia or Not Ventricular Tachycardia , That Remains the Question Clinical Arrhythmias. Arrhytmia Electrophysiol Rev. 2013;23-9.
I.Rilantono L. Penyakit Kardiovaskular (PKV). VI. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2016. 411-417 p.
Perki. Pedoman Tata laksana Sindrom Koroner Akut. Jakarta: Indonesian Heart Association; 2018.
Thaler MS. Aritmia. In: Novrianti dr. A, Ginawati D, editors. The Only EKG Book Youll Ever Need. 7th ed. Jakarta: EGC; 2015. p. 117-8.
Rawshani D. Ventricular tachycardia (VT): ECG criteria, causes, classification, treatment (management). In: Clinical ECG Interpretation. 2nd ed. ECG & Echocardiography Education; 2021.
Deshmukhsamuel DJ, May JAM, Kashou AH, Noseworthy PA, Desimone C V. Wide Complex Tachycardia Differentiation: A Reappraisal of the State of the Art. Am Hear Assoc. 2020;9.
Dharma S. Cara Mudah Membaca EKG. Jakarta: EGC; 2015. 23 p.
Gagal Jantung. In: Buku Ajar Ilmu Penyakit Dalam. VI. Interna Publishing; 2015. p. 1134-6.
Tachycardia With a Pulse Algorithm. ACLS Training Center; 2021 p. 2940.
Perki, IDI. ACLS Indonesia. In: Buku Ajar Kursus Bantuan Hidup Jantung Lanjut. Jakarta; 2020. p. 67-9.
Leni Agnes Siagian. Tatalaksana Takikardia Ventrikel. Contin Med Educ. 2018;45(9):10-2.
Downloads
Additional Files
Published
Issue
Section
License
Authors retain copyright and grant the journal right of first publication and this work is licensed under a Creative Commons Attribution-ShareAlike 4.0 that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
All articles in this journal may be disseminated by listing valid sources and the title of the article should not be omitted. The content of the article is liable to the author.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
In the dissemination of articles, the author must declare the AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh Journal as the first party to publish the article.